## Amendments to the Claims

This listing of claims will replace all prior listings of claims in the application.

## Listing of Claims

## 1.-19. (Canceled)

- 20. (New) A method of immunosuppressing a mammal, comprising administering a composition comprising an antigen recognized by a CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cell to the mammal.
- 21. (New) The method as claimed in claim 20, in which the mammal is a human being.
- 22. (New) The method as claimed in claim 20, additionally comprising a step of administering Interferon- $\gamma$  to boost the immune response from the mammal.
- 23. (New) The method as claimed in claim 20, additionally comprising a step of administering Interleukin 12 and Interleukin 18 to boost the immune response from the mammal.
- 24. (New) The method as claimed in claim 20, in which the immunosuppressing is used to prevent and/or treat an autoimmune disease.
- 25. (New) The method as claimed in claim 20, in which the immunosuppressing is used to prevent and/or treat an allergic disease.
- 26. (New) The method as claimed in claim 20, in which the immunosuppressing suppresses a rejection reaction and/or a

graft-versus-host reaction in an organ or tissue transplantation.

- 27. (New) The method as claimed in claim 20, in which the antigen recognized by the  $\mathrm{CD4}^+\mathrm{CD25}^+$  regulatory T cell comprises a molecule identified by a SEREX method.
- 28. (New) The method as claimed in claim 20, in which the composition comprises an expression vector that encodes an antigen recognized by a  $CD4^+CD25^+$  regulatory T cell.
- 29. (New) The method as claimed in claim 28, in which the antigen recognized by the CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cell comprises a molecule identified by the SEREX method.
- 30. (New) The method as claimed in claim 27, in which the molecule identified by the SEREX method comprises an autoantigen.
- 31. (New) The method as claimed in claim 27, in which the molecule identified by the SEREX method comprises one selected from the group consisting of DnaJ-like2, Galectin-8, poly(A)-binding protein, and Ligase-1.
- 32. (New) The method as claimed in claim 28, in which a gene gun is used for administration of the composition.
- 33. (New) The method as claimed in claim 21, additionally comprising a step of administering Interleukin 12 and Interleukin 18 to boost the immune response from the human being.
- 34. (New) The method as claimed in claim 21, in which the immunosuppressing is used to prevent and/or treat an autoimmune disease.

- 35. (New) The method as claimed in claim 21, in which the immunosuppressing is used to prevent and/or treat an allergic disease.
- 36. (New) The method as claimed in claim 21, in which the immunosuppressing suppresses a rejection reaction and/or a graft-versus-host reaction in an organ or tissue transplantation.
- 37. (New) The method as claimed in claim 29, in which the molecule identified by the SEREX method comprises an autoantigen.
- 38. (New) The method as claimed in claim 29, in which the molecule identified by the SEREX method comprises one selected from the group consisting of DnaJ-like2, Galectin-8, poly(A)-binding protein and Ligase-1.
- 39. (New) The method as claimed in claim 29, in which a gene gun is used for administration of the composition.